Clinical trials: Autoimmune Chronic Spontaneous Urticaria
Non-autoreactive Chronic Spontaneous Urticaria, Autoimmune Chronic Spontaneous Urticaria
Profiling Urticaria for the Identification of Subtypes
The primary purpose of this study is to identify and characterize novel diagnostic markers for autoimmune urticaria, a subset of chronic spontaneous urticaria.
- Conditions
- Non-autoreactive Chronic Spontaneous Urticaria, Autoimmune Chronic Spontaneous Urticaria, Autoreactive, Non-autoimmune Chronic Spontaneous Urticaria
- Trial name
- PURIST (NCT01637116)
- Where
- Germany
- Volunteers
- 195 people
- Sponsor
- Marcus Maurer
Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS)
SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)
The goal of this observational study is to comprehensively profile six immune-mediated inflammatory diseases, including atopic dermatitis (AD), plaque psoriasis (PSO), hidradenitis suppurativa (HS), cutaneous T-cell lymphoma…
- Conditions
- Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO), Atopic Dermatitis (AD)
- Trial name
- SKINERGY (NCT07021495)
- Where
- 8 sites in Netherlands
- Volunteers
- 840 people, healthy volunteers welcome
- Sponsor
- Leiden University Medical Center
Chronic Spontaneous Urticaria
A Study to Assess Subcutaneous Lirentelimab (AK002) in Chronic Spontaneous Urticaria
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous lirentelimab (AK002) in adult subjects with H-1 antihistamine refractory chronic spontaneous…
- Trial name
- MAVERICK (NCT05528861)
- Testing
- Lirentelimab (AK002)
- Where
- 67 sites in United States, Germany and 1 more
- Volunteers
- 127 people
- Sponsor
- Allakos Inc.
Type 2 Inflammatory Disorders
Compassionate Use or Expanded Access of Dupilumab
Provide Compassionate Use or Expanded Access of Dupilumab
- Trial name
- NCT04776694
- Testing
- Dupilumab
- Sponsor
- Regeneron Pharmaceuticals
Chronic Urticaria
Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria
Chronic urticaria can be defined as the occurrence of widespread daily or almost daily wheals for at least 6 weeks, which may be accompanied by angioedema.
- Trial name
- NCT01713725
- Testing
- Omalizumab
- Where
- 4 sites in Spain
- Volunteers
- 20 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra